Shots:
- Sino Biopharmaceutical has entered into an exclusive license agreement with AstraZeneca for the development, manufacturing & commercialization of TQC3721, an inhaled PDE3/4 inhibitor
- As per the deal, AstraZeneca secured exclusive rights to develop, manufacture, & commercialize TQC3721 outside China, along with exclusive global rights to select future development programs
- In return, Sino will receive $200M upfront, with additional development, regulatory & sales milestones, totalling up to $1.9B, as well as tiered royalties ranging up to double-digit percentages
Ref: Sino Biopharma | Image: Sino Biopharma & AstraZeneca | Press Release
Related News: CSPC Group and AstraZeneca Partner to Develop siRNA Drugs in ~$1.77B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
